Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 132.02B +86.9% |
| Revenue (ttm) | 51.58B +4.1% |
| Net Income | 2.10B |
| EPS | 1.79 |
| Shares Out | n/a |
| PE Ratio | 62.77 |
| Forward PE | 13.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 983,311 |
| Open | 11,310 |
| Previous Close | 11,010 |
| Day's Range | 10,970 - 11,450 |
| 52-Week Range | 6,082 - 11,530 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
Teva Pharmaceutical Industries NYSE: TEVA reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company s...
Teva's immune disorder drug meets main goal in mid-stage trial
Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a m...
Teva Pharmaceutical Industries Transcript: Study result
TEV-408, an anti-IL-15 antibody, demonstrated statistically and clinically significant protection of gut architecture and symptom improvement in a phase II-A celiac disease study, with a strong safety profile and single-dose efficacy over three months. Plans are underway for rapid advancement to phase II/III and expansion into additional indications.
Teva Pharmaceutical Industries Slides: Study result
Teva Pharmaceutical Industries has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Teva Pharmaceutical Industries Press release: Study result
Teva Pharmaceutical Industries issued a press release on September 2, 2026, disclosing material business information to investors.
Teva reports TEV ‘408 study met primary endpoint
Teva (TEVA) announced topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met its primary e...
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Teva reports positive Phase 2a results for Teva-discovered TEV '408, showing significant prevention of gluten-induced intestinal damage in celiac disease.
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
Teva to lower cost of select medicines for American patients covered by Medicaid
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva, announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When...
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared c...
Teva unit bids to acquire neuroscience product from BioXcel Therapeutics
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (TEVA) announced it has made a bid to acquire an innovative neuroscience product from BioXcel Therapeutics (BTAI...
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disor...
BioXcel Therapeutics enters asset sale agreement with Teva
BioXcel Therapeutics (BTAI) announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (TEVA), for substant...
Aurinia settles patent litigation with Teva
Aurinia Pharmaceuticals (AUPH) announced that it and its subsidiary, Aurinia Pharma U.S., Inc., have entered into a settlement agreement with Teva Pharmaceuticals Inc. (TEVA) to resolve patent infring...
Aurinia Settles Patent Litigation with Teva
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer
Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome moved a step closer. Ecopipam Application Accepted The...
Teva announces FDA acceptance of ecopipam NDA
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva, announced that the FDA accepted the new drug application, or NDA, for ecopipam, with a targeted action date late in the first…
U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U...
Teva price target raised to $42 from $40 at Barclays
Barclays raised the firm’s price target on Teva (TEVA) to $42 from $40 and keeps an Overweight rating on the shares post the Q2 report. The firm sees potential for…
Humana agrees not to reference Teva's Israel ties at US drug trial
Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly...
Teva seeks to keep Israel ties from jury, cites Gaza war
Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from telling jurors it is an Israeli company at a major drug price-fixing trial, arguing that strong public views over the Gaza ...
Why Teva Pharmaceutical Stock Surged This Week
Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The company's forward guidance didn't deliver big surprises, but it looked solid enough.
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
Teva Pharmaceutical Industries NYSE: TEVA reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were lar...
Teva Pharmaceutical Industries Earnings Call Transcript: Q2 2026
Q2 2026 saw strong growth in innovative products, offsetting generics decline, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow rose 31%, and the company advanced its pipeline and biosimilars portfolio while maintaining disciplined capital allocation.
Teva Pharmaceutical Industries Slides: Q2 2026
Teva Pharmaceutical Industries has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.